Oral drug delivery is the most desirable and preferred method of administering therapeutic agent for their systematic effects such as patient acceptance, convenience in administration, and cost-effective manufacturing process. Thus, a wide variety of approaches of drug delivery system (DDS) have been investigated for oral application.1) However, the development process is precluded by several physiological difficulties, such as an inability to restrain and localize the DDS within desired regions of gastrointestinal tract and highly variable nature of gastric emptying process. For example, the relatively brief gastric emptying time (GET) can result in incomplete drug release from the DDS devices leading to diminished efficacy of the administered dose.Intragastric floating drug delivery system (FDDS) is noted as one of the orally applicable DDS for prolongation of the GET.2-4) The bulk density of FDDS is lower than that of gastric fluids and thus it remains buoyant on stomach contents for a long time in the drug releasing process. Hence, it is useful for obtaining the sufficient bioavailability and the effective "plasma" level, especially for drug having limited absorption sites in the upper small intestine, such as furosemide, 5) ketoprofen. 6) In addition, FDDS is one of the optimal systems for stomach mucosa targeting of antitumor agent for the treatment of stomach cancer 7) and antibiotics for the eradication of Helicobacter pylori.8) However, with most of FDDS devices developed previously, it is difficult for all patients to obtain the expected therapeutic effects of drug administered, since the drug is released with a pattern preprogrammed in the manufacturing process despite individual differences in stomach such as pH value and the transit time in gastrointestinal tract. Thus, from a viewpoint of the real optimization of drug therapy, the drug release properties of FDDS should be adjusted to individual stomach conditions.Over the years, in a series on preparation of double-compressed (DC) tablets for use in a DDS with plasma techniques, we have reported that novel sustained-and delayedrelease systems can be prepared by plasma-irradiation on the outer layer of DC tablet, [9][10][11][12][13][14][15][16][17][18][19] as well as matrix-type composite powder for sustained-drug release system can be prepared by mechanically-amplified plasma processing. [20][21][22] During the course of such studies on plasma-assisted DDS preparation, we have found that the carbon dioxide was trapped in the tablet when argon plasma was irradiated onto the DC tablet composed of plasma-crosslinkable polymers possessing carboxyl group as an outer layer. Since such tablets turned to floating system on the water, it was considered that this could be applicable to FDDS. In fact, we have obtained the intragastric FDDS by plasma-irradiation on DC tablet using a mixture of methyl vinyl ether-maleic acid copolymer (VEMAC) and hydroxypropylmethylcellulose phthalate (HPMCP) with plasma-crosslinkable properties as outer layer. The tablet thus ...